Want to see what we’re working on?
Stay in the loop
For the latest updates as they happen, follow us on LinkedIn.
First 100 days on the job: Q&A with Mauro Chies
After his first 100 days as CEO, Mauro Chies shares his thoughts on the organization, his experiences and what he sees for the future of the pCPA
Cancer drugs being negotiated faster than ever
New data shows negotiation timelines for oncology drugs dropped to 5 months in 2024, their lowest level ever
The pCPA launches new visual brand identity
We are thrilled to announce the launch of a refreshed brand identity, marking a significant milestone in our evolution toward a more modern organization.
The pCPA announces its new CEO
The pCPA Board of Directors is pleased to announce the appointment of Mauro Chies as chief executive officer (CEO).
Making it easier for brand-name drug manufacturers to contact us
The pCPA has launched a new, dedicated email address for brand drug manufacturers.
2023–24 pCPA impact report: Progress in motion
The pCPA Board of Directors is happy to announce the release of the 2023–24 impact report.
New process for generic-drug price change submissions
We’ve introduced a faster and easier way for manufacturers to submit price change requests for generic drugs.
Introducing the new chair and vice-chair of our Board
We are pleased to announce our new chair and vice-char of our Board
The pCPA welcomes our acting deputy CEO
The pCPA is pleased to announce that Dr. Clifford Lo will be joining the pCPA team as acting deputy CEO.
Deputy CEO Dominic Tan assumes CEO duties of pCPA
Effective May 10, 2024, Dominic Tan has assumed the responsibilities of CEO of the pCPA on an interim basis.